IBRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ImmunityBio Inc (IBRX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown significant year-over-year growth in ANKTIVA sales and analysts maintain a Buy rating with a reduced price target of $12, the lack of strong technical signals, neutral trading sentiment, and speculative nature of the investment make it less suitable for the given investor profile. The stock may be better suited for speculative investors willing to take on higher risk.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 58.513, and moving averages are converging, suggesting indecision in price action. The stock is trading near its resistance level of 7.368, with support at 6.78. Overall, the technical indicators do not provide a strong buy signal.
Significant year-over-year growth in ANKTIVA sales (+168%).
Analysts maintain a Buy rating with a price target of $12, indicating potential upside.
Lack of strong technical signals or clear bullish momentum.
The stock is suggested as a speculative investment, which may not align with the investor's long-term, beginner-focused strategy.
No significant insider or hedge fund activity to support a strong buy case.
No detailed financial data available for analysis. However, Q1 results showed $44.2M in ANKTIVA sales, up 15% quarter-over-quarter and 168% year-over-year, indicating strong product growth.
BTIG lowered the price target from $13 to $12 but reaffirmed a Buy rating, citing strong growth in ANKTIVA sales.
